Advancing
cannabinoid-based
and targeted therapies
for the treatment of
coronavirus and cancer

Pascal Biosciences is dedicated to improving the lives of patients suffering from life-threatening diseases including COVID-19 and intractable cancers such as glioblastoma. We are developing novel cannabinoid-based small molecules and targeted antibodies, focusing on treatments for SAR-CoV-2 infection and cancers for which there are no adequate therapies.

Cannabinoid for COVID-19

In a cell-based assay, Pascal has identified a cannabinoid that blocks SARS-CoV-2 with a potency similar to remdesivir.

Learn More

PAS-403 for Glioblastoma

PAS-403 is a cannabinoid-based small molecule that utilizes a unique mechanism of action to kill cancer cells.  Clinical trials are targeted to begin in 2021.

Learn More

PAS-393 for Cancer

PAS-393 is a cannabinoid that makes cancers visible to the immune system.

Learn More

Pre-BCR Antibody for Leukemia

The pre-BCR antibody targets leukemia cells without harming the normal immune system.

Learn More

About Pascal Biosciences

Pascal Biosciences (TSX-V:PAS, FSE:6PB.F) is a biopharmaceutical company focused on advancing innovative approaches for the treatment of cancer.

Learn More

Stay Informed